- $55.15m
- $64.20m
- $0.20m
Clene Q2 net loss widens on higher other expenses
Clene Inc expected to post a loss of 37 cents a share - Earnings Preview
Brief: Clene Inc - Enters Second Amendment To Senior Secured Convertible Notes - SEC Filing
Clene Q1 loss widens on warrant liability issuance costs
Brief: Clene Inc - Announces Common Stock Offering - SEC Filing
Brief: Clene Announces $7 Million Underwritten Offering Of Common Stock
Brief: After Successful FDA Meeting, Clene Filing Accelerated Approval NDA For Als
Clene 2025 net loss narrows as expenses fall
Brief: Clene Announces Additional Cnm-Au8 Biomarker Data Supporting Potential NDA Filing For Upcoming In-Person FDA Meeting
Brief: Clene Announces Registered Direct Offering Of Over $28 Million
Brief: Clene Announces Statistically Significant ALS Biomarker Results
Biopharma firm Clene reports Q3 net loss of $8.8 mln
Brief: Clene Inc - Files Prospectus Supplement For $6.28 Million Shares - SEC Filing
Clene Inc. expected to post a loss of 47 cents a share - Earnings Preview
Brief: Clene Inc FDA Confirms Als Survival Data Type C Meeting & End-Of-Phase 2 Type B MS Program Meeting For Q3 2025
Brief: Clene Provides Regulatory Update Following Constructive FDA Type-C Meeting On Neurofilament Biomarker Analysis Plan And Confirms Two Additional FDA Meetings
Clene Inc. expected to post a loss of 95 cents a share - Earnings Preview
Brief: Clene Inc. - Enters Equity Distribution Agreement With Canaccord - SEC Filing
U.S. RESEARCH ROUNDUP-3M, Intuit, Starbucks